237 related articles for article (PubMed ID: 20420567)
1. Clinical molecular imaging with PET agents other than 18F-FDG.
Hall LT; Struck AF; Perlman SB
Curr Pharm Biotechnol; 2010 Sep; 11(6):545-54. PubMed ID: 20420567
[TBL] [Abstract][Full Text] [Related]
2. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
3. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging: 18F-FDG PET and a whole lot more.
Peterson TE; Manning HC
J Nucl Med Technol; 2009 Sep; 37(3):151-61. PubMed ID: 19692452
[TBL] [Abstract][Full Text] [Related]
5. PET beyond ¹⁸F-FDG: second generation PET tracers in clinical oncology.
Brouwers AH; Glaudemans AW; De Vries EF
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):1-3. PubMed ID: 25854554
[No Abstract] [Full Text] [Related]
6. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
7. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
8. 18F FDG-PET imaging in musculoskeletal infection.
Stumpe KD; Strobel K
Q J Nucl Med Mol Imaging; 2006 Jun; 50(2):131-42. PubMed ID: 16770303
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-EC-deoxyglucose-- poor man's 18F-FDG: what will be the future of PET in molecular imaging?
Uz Zaman M
Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):429. PubMed ID: 17143646
[No Abstract] [Full Text] [Related]
10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
14. PET/MR imaging: current and future applications for cardiovascular disease.
Naeger DM; Behr SC
Magn Reson Imaging Clin N Am; 2015 Feb; 23(1):95-103. PubMed ID: 25476678
[TBL] [Abstract][Full Text] [Related]
15. Quantification in clinical fluorodeoxyglucose positron emission tomography.
Hallett WA
Nucl Med Commun; 2004 Jul; 25(7):647-50. PubMed ID: 15208490
[TBL] [Abstract][Full Text] [Related]
16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
17. (18)F-FDG PET/CT imaging in granulomatosis with polyangiitis.
De Geeter F; Gykiere P
Hell J Nucl Med; 2016; 19(1):5-6. PubMed ID: 26929934
[TBL] [Abstract][Full Text] [Related]
18. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
19. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
Schaarschmidt BM; Gomez B; Buchbender C; Grueneisen J; Nensa F; Sawicki LM; Ruhlmann V; Wetter A; Antoch G; Heusch P
Diagn Interv Radiol; 2017; 23(2):127-132. PubMed ID: 28089955
[TBL] [Abstract][Full Text] [Related]
20. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
